OncoMatch/Clinical Trials/NCT05316467
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
Is NCT05316467 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Megestrol Acetate 160 MG Oral Tablet for endometrial carcinoma.
Treatment: Megestrol Acetate 160 MG Oral Tablet — To investigate the efficacy of weight management plus megestrol acetate in obese patients with early endometrioid carcinoma（EEC）asking for fertility-sparing treatment
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Disease stage
Grade: g1
Prior therapy
Cannot have received: high potency progestin
Cannot have received: oral contraceptives
Lab requirements
Kidney function
kidney dysfunction (creatinine clearance <30 mL/min)
Liver function
alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels elevate to 3 times or more of the upper limit of normal
Combined with severe medical disease or liver or kidney dysfunction: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels elevate to 3 times or more of the upper limit of normal, kidney dysfunction (creatinine clearance <30 mL/min)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify